Humacyte (HUMA) Accumulated Expenses (2020 - 2026)

Humacyte (HUMA) has 7 years of Accumulated Expenses data on file, last reported at $8.7 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $8.7 million, down 10.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (down 10.56% YoY), and the FY2025 annual result was $10.5 million, changed N/A from the prior year.
• Accumulated Expenses declined to $8.7 million in Q1 2026 per HUMA's latest filing, from $10.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.2 million in Q3 2024 and troughed at $173000.0 in Q1 2022.
• A 5-year average of $7.2 million and a median of $8.8 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses slumped 95.7% in 2022, then surged 5441.04% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $7.1 million in 2022, then jumped by 31.4% to $9.3 million in 2023, then advanced by 19.39% to $11.2 million in 2024, then decreased by 5.48% to $10.5 million in 2025, then retreated by 17.68% to $8.7 million in 2026.
• Business Quant data shows HUMA's Accumulated Expenses at $8.7 million in Q1 2026, $10.5 million in Q4 2025, and $10.3 million in Q3 2025.